Literature DB >> 14984680

The epidemiology and impact of migraine.

Marcelo E Bigal1, Richard B Lipton, Walter F Stewart.   

Abstract

Migraine is a highly prevalent headache disorder that has a substantial impact on the individual and society. In this article, we review the burden of migraine, emphasizing the population-based studies that used standardized diagnostic criteria. We highlight descriptive epidemiology, burden of disease, patterns of diagnosis, and treatment. We focus on the epidemiology and burden of probable migraine, a subtype of migraine where just one clinical feature is missing. We finish by describing approaches to improving healthcare delivery for migraine and probable migraine. Although migraine is a remarkably common cause of temporary disability, many migraineurs, even those with disabling headache, have never consulted a physician for the problem. Prevalence is highest in women, in persons between the ages of 25 and 55 years, and, at least in the United States, in individuals from low-income households. Nonetheless, prevalence is high in groups other than these high-risk groups. Probable migraine is a prevalent form of migraine, and like migraine with and without aura it produces decrements in health-related quality of life and increments in disability relative to control subjects.

Entities:  

Mesh:

Year:  2004        PMID: 14984680     DOI: 10.1007/s11910-004-0022-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  37 in total

1.  Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial.

Authors:  R C Cady; R Ryan; P Jhingran; S O'Quinn; D G Pait
Journal:  Arch Intern Med       Date:  1998-05-11

2.  Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis.

Authors:  R B Lipton; W F Stewart; D D Celentano; M L Reed
Journal:  Arch Intern Med       Date:  1992-06

3.  Healthcare resource and lost labour costs of migraine headache in the US.

Authors:  J T Osterhaus; D L Gutterman; J R Plachetka
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

4.  A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life.

Authors:  C Dahlöf; J Bouchard; P Cortelli; J Heywood; J P Jansen; S Pham; J Hirsch; J Adams; D W Miller
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

5.  Diagnosis of migraine: empirical analysis of a large clinical sample of atypical migraine (IHS 1.7) patients and proposed revision of the IHS criteria.

Authors:  J C Rains; D B Penzien; G L Lipchik; N M Ramadan
Journal:  Cephalalgia       Date:  2001-06       Impact factor: 6.292

6.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

7.  Childhood migraine in Nigeria--I: A community-based study.

Authors:  G I Orji; S O Iloeje
Journal:  West Afr J Med       Date:  1997 Oct-Dec

8.  Medical consultation for migraine: results from the American Migraine Study.

Authors:  R B Lipton; W F Stewart; D Simon
Journal:  Headache       Date:  1998-02       Impact factor: 5.887

9.  A nationwide survey of migraine in France: prevalence and clinical features in adults. GRIM.

Authors:  P Henry; P Michel; B Brochet; J F Dartigues; S Tison; R Salamon
Journal:  Cephalalgia       Date:  1992-08       Impact factor: 6.292

10.  Impact of migraine in the United States: data from the National Health Interview Survey.

Authors:  P E Stang; J T Osterhaus
Journal:  Headache       Date:  1993-01       Impact factor: 5.887

View more
  29 in total

Review 1.  Guideline for primary care management of headache in adults.

Authors:  Werner J Becker; Ted Findlay; Carmen Moga; N Ann Scott; Christa Harstall; Paul Taenzer
Journal:  Can Fam Physician       Date:  2015-08       Impact factor: 3.275

2.  [Alimentary trigger factors that provoke migraine and tension-type headache].

Authors:  J Holzhammer; C Wöber
Journal:  Schmerz       Date:  2006-04       Impact factor: 1.107

Review 3.  Association Between Obesity and Migraine in Women.

Authors:  Jelena M Pavlovic; Julio R Vieira; Richard B Lipton; Dale S Bond
Journal:  Curr Pain Headache Rep       Date:  2017-08-25

4.  Adverse reactions related to drugs for headache treatment: clinical impact.

Authors:  Anna Ferrari; Alessandra Ottani; Alfio Bertolini; Arrigo Francesco Giuseppe Cicero; Ciro Pio Rosario Coccia; Sheila Leone; Emilio Sternieri
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

5.  Effect of Prayer on Intensity of Migraine Headache: A Randomized Clinical Trial.

Authors:  Haleh Tajadini; Nasser Zangiabadi; Kouros Divsalar; Hossein Safizadeh; Zahra Esmaili; Hossein Rafiei
Journal:  J Evid Based Complementary Altern Med       Date:  2016-02-09

Review 6.  Chronic disorders with episodic manifestations: focus on epilepsy and migraine.

Authors:  Sheryl R Haut; Marcelo E Bigal; Richard B Lipton
Journal:  Lancet Neurol       Date:  2006-02       Impact factor: 44.182

Review 7.  Migraine and cerebrovascular disease: still a dangerous connection?

Authors:  Elio Clemente Agostoni; Marco Longoni
Journal:  Neurol Sci       Date:  2018-06       Impact factor: 3.307

8.  Long-term effects of a sensitisation campaign on migraine: the Casilino study.

Authors:  B Petolicchio; L Di Clemente; M Altieri; E Vicenzini; G L Lenzi; Vittorio Di Piero
Journal:  J Headache Pain       Date:  2010-04       Impact factor: 7.277

Review 9.  Correlation or causation: untangling the relationship between patent foramen ovale and migraine.

Authors:  Eric Adler; Barry Love; Steve Giovannone; Frank Volpicelli; Martin E Goldman
Journal:  Curr Cardiol Rep       Date:  2007-03       Impact factor: 2.931

10.  Prophylaxis of migraine.

Authors:  Ivan Garza; Jerry W Swanson
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.